PITTSBURGH–(BUSINESS WIRE)–Helomics® Corporation, a privately-held, personalized healthcare company
that provides comprehensive tumor profiling utilizing proprietary live
cell and fixed cell products and services, announced today the start of
a second phase of corporate realignment towards becoming an integrated
clinical research and clinical products company. During this
restructuring the laboratory operations at Helomics, including the
processing of its ChemoFx, GeneFX, BioSpeciFx, CellFx and DEFENDER tumor
profiling tests, will continue at full capacity.
As part of this second realignment phase, Helomics will restructure its
R&D, operations, and sales and marketing to refocus its efforts on the
central buying and decision-making processes of Medicare, Commercial
Payer’s and hospital systems. To reflect this realignment, a
reduction-in-force was also completed, primarily sales professionals
calling on individual oncologists.
This strategic shift was brought on primarily by changes resulting from
the Affordable Care Act (ACA), which have made cost the sole driver for
healthcare decision-making, to the determent of new technologies and
diagnostics in the personalized medicine arena. Due to this, the
decision-making process for the utilization of new technologies has
shifted into a more centralized process.
In parallel, Helomics is forming a new research products division that
will focus on the pharmaceutical, biotech and clinical research sectors.
The company’s clinical products business will also be restructured into
a new division focused on advanced lab developed tests (ALDT) and
preparation for products in the FDA diagnostics markets as the
regulatory oversight begins to shift in the personalized medicine
Neil J. Campbell, President & CEO of Helomics, said, “Helomics’
objective in this second phase of realignment is to provide an even
greater focus on leveraging our comprehensive tumor profiling
technologies and expertise, and aligning our resources to best serve the
current Payer environment is critical at this stage. Comprehensive tumor
profiling through PCAP™ done properly will focus on the life cycle of
the patients’ tumor during all stages such as cell oncogenesis,
proliferation, metastasis, apoptotic cascade. Helomics’ broad set of
proprietary platforms and products can provide an in depth understanding
of tumor biology and the effects pharmaceutical and immunotherapeutic
interventions can have on the personalized treatments of patients.”
To access a CEO letter from Neil Campbell discussing this second phase
of realignment further, please visit http://www.helomics.com/
The PCAP™ platform is the basis of Helomics’ comprehensive tumor
profiling capability. The platform consists of a suite of technologies
for the live and fixed cell analysis of changes in a tumor’s gene
regulation, protein expression, and cellular morphology over time. The
PCAP™ platform has spawned new products that can elucidate tumor biology
characterization with therapeutic mechanisms of action to highlight drug
treatment options based upon the holistic tumor characterization instead
of cell sensitivities only.
About Helomics® Corporation, Inc.
Helomics® is a comprehensive personalized healthcare company, bringing
the next generation of diagnostics to the oncology field. Helomics is
dedicated to improving patient outcomes by providing a personalized
comprehensive tumor profile utilizing a proprietary set of laboratory
platforms that leverage both live and fixed cellular based analysis
allowing physicians to characterize malignant tumors on a personalized
basis. Helomics’ novel molecular and cellular markers and bioinformatics
services support mechanistic tumor characterization and treatment
decisions by providing vital information based on the specific
biological processes of each individual’s cancer. Helomics is
headquartered in Pittsburgh, Pennsylvania where the company maintains
two CLIA-certified laboratories. For more information please visit: www.helomics.com.
This release may contain forward-looking statements that involve risks
and uncertainties. Market conditions and other important factors could
cause actual results to differ materially from those communicated in any
forward-looking statements, information disclosed in presentations,
conference calls or other public venues. We do not intend to update any
forward-looking statements after the date of this press release.